menu
    • menu
    [{"orgOrder":0,"company":"Hesperos","sponsor":"Dianthus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1S","graph1":"Immunology","graph2":"Phase II","graph3":"Hesperos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hesperos \/ Hesperos","highestDevelopmentStatusID":"8","companyTruncated":"Hesperos \/ Hesperos"},{"orgOrder":0,"company":"Hesperos","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Riliprubart","moa":"C1S","graph1":"Neurology","graph2":"Phase II","graph3":"Hesperos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hesperos \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hesperos \/ Sanofi"},{"orgOrder":0,"company":"Hesperos","sponsor":"Psilera","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"PSIL-006","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Hesperos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hesperos \/ Psilera","highestDevelopmentStatusID":"4","companyTruncated":"Hesperos \/ Psilera"}]

    Find Clinical Drug Pipeline Developments & Deals by Hesperos

    Menu

    Hesperos

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PSIL-006

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Psilera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Psilera Collaborates with Drug Development Leader Hesperos to Advance PSIL-006

                            Details : The collaboration aims to accelerate the preclinical development of Psilera's lead compound, PSIL-006, targeting frontotemporal dementia (FTD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 09, 2025

                            Lead Product(s) : PSIL-006

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Psilera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : Dianthus Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hesperos Supports Investigational Product for Phase II Trial with Human-on-a-Chip®

                            Details : DNTH103 is an investigational, potent mAb engineered to selectively targets by inhibiting only the active form of the C1s protein. It is being evaluated for generalized myasthenia gravis.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : DNTH103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : Dianthus Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Hesperos

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riliprubart

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neurom...

                            Details : SAR445088, a complement inhibitor formerly known as BIVV020, has entered a study in adults with persistent/chronic immune thrombocytopenia (ITP), is currently undergoing Phase II Clinical trial.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 19, 2022

                            Lead Product(s) : Riliprubart

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth